Oak Hill Bio and Chiesi enrol first European patient in bronchopulmonary dysplasia treatment study

Oak Hill Bio and Chiesi Group have launched a study of a revolutionary bronchopulmonary dysplasia treatment for extremely premature infants.

The post Oak Hill Bio and Chiesi enrol first European patient in bronchopulmonary dysplasia treatment study appeared first on Innovation News Network.